Corindus Introduces CorPath GRX System in Japan With Postmarket Study
April 15, 2019—Corindus Vascular Robotics, Inc. announced the commercial introduction of the company's CorPath GRX system for robotic-assisted percutaneous coronary interventions (PCIs) in Japan. These first PCIs performed with the device mark initial enrollment in the postmarket study in Japan.
In June 2018, Corindus announced that the CorPath GRX received approval from Japan's Pharmaceutical and Medical Device Agency in 2018 and A1 technical fee reimbursement for Japan in March 2019.
Corindus' Japanese distribution partner is Japan Medicalnext Co., Ltd., a wholly owned entity of MC Healthcare, Inc. (a subsidiary of Mitsubishi Corporation).
The first clinical procedures in Japan were performed by Takafumi Ueno, MD, PhD, Director of Interventional Cardiology, Center of Cardiovascular Disease, Kurume University Hospital in Kurume, Japan.
In the company's announcement, Dr. Ueno commented, “After completing the first cases with CorPath GRX, I am impressed with the capabilities of the system, including the level of precision and control during complex procedures. Robotics will provide Japan with cutting-edge technology in interventional medicine, and we are pleased to be one of the first facilities in the Asia-Pacific region to offer this treatment to our patients.”